Endocrinology’s brightest minds will gather once again in San Francisco from July 12–15 for ENDO 2025. Showcasing groundbreaking research, cutting-edge clinical advances, and abstract discussions on the future of hormone science and care, our signature conference promises a transformative experience for researchers, clinicians, and healthcare leaders alike. While San Francisco sets the stage for ENDO...
Bypass and Beyond: Redefining Roles and Mechanisms of Obesity Treatment at ENDO 2025
Endocrine News talks with the chair and presenters of “Bariatric Surgery and Emerging Medications: Redefining Roles and Mechanisms,”an ENDO 2025 session that analyzes a variety of factors that are impacted by bariatric surgery including postsurgical hypoglycemia, surgery versus pharmacological solutions, as well as a number of molecular mechanisms of the surgery itself. With so many...
Easy Targets: How Endocrine-Disrupting Chemicals Affect Reproductive Endocrinology

Sriram Gubbi of NIDDK Wins Endocrine Society’s 2025 Endocrine Images Art Competition
Weighing In: Making Obesity Treatment More Effective and Accessible by 2030
Harsh Realities: How Treating Obesity Across the Lifespan Continues to Evolve
Fatima Cody Stanford, MD, MPH, MPA, MBA, takes the lessons she learned growing up in Atlanta serving her community and applies them to her work treating obesity. In July, she’ll give the plenary presentation at ENDO 2025, “Changing the Game of Obesity Care Across Lifespan: Policies, Diets, and Drug Innovation,” offering attendees a comprehensive overview...
What do podcasting, grant writing, microaggressions, and retirement all have in common? They are all topics covered by new Professional Development Workshops at ENDO 2024! When attendees descend on Boston in June for ENDO 2024, they will have the opportunity to participate in a series of workshops that will enhance their visibility in the endocrine...
Five abstracts from Crinetics Pharmaceuticals’s clinical development programs, including four late-breaking abstracts, will be presented at the Endocrine Society’s annual meeting, ENDO 2024, taking place June 1-4, 2024 in Boston – including initial data from a Phase 2 Trial of atumelnant in congenital adrenal hyperplasia (CAH). “This year’s Endocrine Society meeting represents a major milestone for...